Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2011 May-Jun;59(3):191-6.
doi: 10.4103/0301-4738.81023.

Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration

Partha Biswas  1 , Subhrangshu Sengupta, Ruby Choudhary, Subhankar Home, Ajoy Paul, Sourav Sinha
Affiliations
Randomized Controlled Trial

Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration

Partha Biswas et al. Indian J Ophthalmol. 2011 May-Jun.

Abstract

Context: Ranibizumab and bevacizumab are used widely for treating patients with choroidal neovascular membrane (CNVM) secondary to age-related macular degeneration (AMD).

Aims: To determine and compare the efficacy and safety of intravitreal ranibizumab and bevacizumab in treatment of CNVM due to AMD.

Settings and design: Prospective comparative case series carried out in an eye institute and eye department of a hospital in Kolkata, India.

Materials and methods: One hundred and four eyes with CNVM due to AMD were randomized into two groups. Group A (n=54; 24 occult) received monthly intravitreal ranibizumab injections (0.5 mg in 0.05 ml) and Group B (n=50; 22 occult) received monthly bevacizumab injections (1.25 mg in 0.05 ml) for 3 consecutive months and then as per study criteria. Data analysis done using SPSS software. P-value of <0.05 was considered statistically significant.

Results: The mean best corrected visual acuity (BCVA) in the ranibizumab group increased from 58.19 Early Treatment Diabetic Retinopathy Study (ETDRS) letters at baseline to 64 ETDRS letters at month 3 (P<0.001). In bevacizumab group mean BCVA increased from 56.80 to 61.72 ETDRS letters at month 3 (P<0.001). At the end of 18 months, there was no statistically significant difference between groups A and B with respect to change in BCVA (P=0.563) or central macular thickness (CMT; P=0.281), as measured by optical coherence tomography (Stratus OCT 3000). No significant sight-threatening complications developed.

Conclusions: Ranibizumab and bevacizumab are equally safe and efficacious in treating CNVM due to AMD.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

Figures

Figure 1
Figure 1
Average change in mean best corrected visual acuity (ETDRS letters) over 18 months in ranibizumab group (Group A) and bevacizumab group (Group B) (Respective intravitreal injections administered at months 0, 1 and 2 and then as per study criteria)
Figure 2
Figure 2
Change in average central macular thickness (μm) over 18 months in ranibizumab group (group A) and bevacizumab group (group B) (Respective intravitreal injections administered at months 0, 1 and 2 and then as per study criteria)
See this image and copyright information in PMC

References

    1. Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci. 1996;37:1929–34. - PubMed
    1. Otani A, Takagi H, Oh H, Koyama S, Ogura Y, Matumura M, et al. Vascular endothelial growth factor family and receptor expression in human choroidal neovascular membranes. Microvasc Res. 2002;64:162–9. - PubMed
    1. Zarbin M, Szirth B. Current Treatment of Age-Related Macular Degeneration. Optom Vis Sci. 2007;84:559–72. - PubMed
    1. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology. 2005;112:1035–47. - PubMed
    1. First-line treatment of metastatic colorectal cancer [Internet]. FDA Approval for Bevacizumab – National Cancer Institute. [Last cited on 2010 Sep 18]. Available from: http://www.cancer.gov/cancertopics/druginfo/fdabevacizumab#Anchor-Approv... .

Publication types

MeSH terms